Anavex Life Sciences Corp (AVXL)

[Investor2014]

Thank you for these and the sets of notes from our other two posters, much appreciated.

My personal favorite, Major publication will publish data from the Phase 2A trail instead of presenting it at a scientific conf.

Mine too which I hope soon will leave no questions dangling and these two:

No need to have FDA / USA arm for Alz trial. Only needed if getting enough patients is an issue.

There is no magic switch from P2B to a P3. It is one trial. I get the feeling from his answer that they continue to keep a low profile on what they are doing with labeling it a P2b/3. He stated one trial and after this trial design they are done.

Although still leaves us in dark on many details of the trial e.g. doses and how are they going about titration and switching from 2b to 3.

We'll just have to remain intrigued I guess.